Contact-Dermatitis Prevalence in 269 Surgical and Anaesthesia Staff
Doctor’s Notes · Life in Motion · Evidence Review
Editorial disclosure: The featured image is an AI-created illustration of a fictional workplace scene. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.
This review asks one narrow workplace question and keeps the paper’s denominator, design, result and limitations attached. It is education, not a diagnosis or individualized occupational-safety plan.
What did the study actually examine?
| Study element | Reported detail |
|---|---|
| Population | 269 surgical assistants, anaesthesia assistants and anaesthesiologists at Amsterdam UMC. |
| Design | Single-centre cross-sectional questionnaire study with consultation offered to participants with atopy or compatible symptoms. |
| Timepoint | June 1 to July 20, 2022; point and one-year prevalence. |
| Key result | Overall point prevalence was 7.8% (95% CI 4.9–11.7) and one-year prevalence 28.3% (95% CI 23.0–34.0). One-year estimates were 49%, 19% and 3% across the three occupational groups; no sick days were reported. |
| Funding/conflicts available in abstract | Funding or conflicts were not stated in the PubMed abstract. |
How should the result be read?
Overall point prevalence was 7.8% (95% CI 4.9–11.7) and one-year prevalence 28.3% (95% CI 23.0–34.0). One-year estimates were 49%, 19% and 3% across the three occupational groups; no sick days were reported.
The key is to separate three different ideas: a symptom report, a clinician-confirmed dermatitis diagnosis and a positive allergy test. They are not interchangeable. A patch-test reaction indicates sensitization under test conditions; occupational relevance still depends on the exposure history, clinical pattern and timing.
Important limitation: Single-centre self-reported prevalence may not generalize, subgroup sizes and uncertainty are not all shown in the abstract, and consultation attendance was selective.
What can a worker document before an appointment?
- The exact task, material, cleanser, glove, resin, dye, metal, food, dust or equipment used.
- Where symptoms appear, when they begin, and whether they change on days away.
- Product labels and safety data—without placing workplace substances directly on the skin.
- Required PPE, handwashing frequency, heat, friction, sweating and wet-work duration.
- Changes in function, sleep, attendance or the ability to complete specific tasks.
Exposure controls, substitution, engineering measures and correctly selected protective equipment belong in the conversation with occupational health and the employer. Skin-care products do not replace those controls. Seek prompt medical care for severe pain, rapidly spreading redness, drainage, fever, breathing symptoms or major loss of function.
Primary research and guidance
- Primary research record: PubMed PMID 37414086
- NIOSH: occupational skin exposure
- NIAMS: atopic dermatitis overview
- American Academy of Dermatology: eczema skin care
PubMed indexing is not NIH endorsement of the study’s interpretation, this article or any product.
Where a cosmetic moisturizer fits
Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003, and outside research does not become a product result. #003 is not an eczema medicine. This article makes no treatment, cure, prevention, itch-relief, pediatric-safety or 24-hour claim.
Bottom line
This evidence is most useful when its population, denominator and design travel with the number. Use it to sharpen questions about diagnosis, exposure and work design—not to promise that one routine works for every person or job.